INCY

SEC source: 0000879169-24-000138 · wk-form4_1721233824.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,863

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0000879169-24-000137 · wk-form4_1721233791.xml · derivative · entry 3

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,284

Underlying: Common Stock · 16,284 shares

Expires 2034-07-14

F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000137 · wk-form4_1721233791.xml · nonDerivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,076

F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 28,198 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0000879169-24-000137 · wk-form4_1721233791.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,625

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0000879169-24-000136 · wk-form4_1721233758.xml · derivative · entry 2

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,323

Underlying: Common Stock · 13,323 shares

Expires 2034-07-14

F3 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000136 · wk-form4_1721233758.xml · nonDerivative · entry 1

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,479

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 32,479 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.

SEC source: 0000879169-24-000135 · wk-form4_1721233714.xml · derivative · entry 2

Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,921

Underlying: Common Stock · 5,921 shares

Expires 2034-07-14

F3 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000135 · wk-form4_1721233714.xml · nonDerivative · entry 1

Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,474

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 10,474 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000134 · wk-form4_1721233676.xml · derivative · entry 3

CAGNONI PABLO J · CIK 0001205703 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,411

Underlying: Common Stock · 44,411 shares

Expires 2034-07-14

F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000134 · wk-form4_1721233676.xml · nonDerivative · entry 2

CAGNONI PABLO J · CIK 0001205703 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,170

F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 219,502 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0000879169-24-000134 · wk-form4_1721233676.xml · nonDerivative · entry 1

CAGNONI PABLO J · CIK 0001205703 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,919

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0000879169-24-000133 · wk-form4_1721233641.xml · derivative · entry 3

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,189

Underlying: Common Stock · 61,189 shares

Expires 2034-07-14

F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000133 · wk-form4_1721233641.xml · nonDerivative · entry 2

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 496,674

F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 114,696 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000133 · wk-form4_1721233641.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 501,635

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0000879169-24-000132 · wk-form4_1721233574.xml · derivative · entry 3

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,284

Underlying: Common Stock · 16,284 shares

Expires 2034-07-14

F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000132 · wk-form4_1721233574.xml · nonDerivative · entry 2

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,272

F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 28,198 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0000879169-24-000132 · wk-form4_1721233574.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,821

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0000879169-24-000131 · wk-form4_1721233493.xml · derivative · entry 3

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,127

Underlying: Common Stock · 28,127 shares

Expires 2034-07-14

F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000131 · wk-form4_1721233493.xml · nonDerivative · entry 2

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,197

F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 58,275 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000131 · wk-form4_1721233493.xml · nonDerivative · entry 1

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,145

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0000879169-24-000130 · wk-form4_1721233433.xml · derivative · entry 4

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,205

Underlying: Common Stock · 22,205 shares

Expires 2034-07-14

F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000130 · wk-form4_1721233433.xml · nonDerivative · entry 2

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,348

F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

SEC source: 0000879169-24-000130 · wk-form4_1721233433.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,459

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0000879169-24-000118 · wk-form4_1720715703.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,534

F1 · balance_after: This includes an aggregate of 38,597 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000116 · wk-form4_1720023594.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 460,610

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 84,467 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000115 · wk-form4_1720023565.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,682

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 38,597 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000114 · wk-form4_1720023541.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,543

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 22,692 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0000879169-24-000113 · wk-form4_1720023490.xml · nonDerivative · entry 1

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,573

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · price: Includes an aggregate of 48,764 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000112 · wk-form4_1720023464.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,279

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 76,940 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.

SEC source: 0000879169-24-000111 · wk-form4_1720023436.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,347

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 22,692 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0000879169-24-000110 · wk-form4_1720023409.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,790

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 11,836 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000950170-24-080630 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,183,142

F1 · shares: Includes 537 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F1 · ownership.nature: Includes 537 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 11,510 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,830 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 537 RSUs on Table I. The 537 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-080630 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,812,463

F1 · shares: Includes 537 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F1 · ownership.nature: Includes 537 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 11,510 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,830 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 537 RSUs on Table I. The 537 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000879169-24-000102 · wk-form4_1719940951.xml · nonDerivative · entry 1

Clancy Paul J · CIK 0001409601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,014

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000101 · wk-form4_1719940925.xml · nonDerivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,354

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000950170-24-073677 · ownership.xml · derivative · entry 9

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,517

Underlying: Common Stock · 12,517 shares

Expires 2034-06-11

F15 · derivative.exercise_price: Includes 12,517 Stock Options granted by the Issuer to Julian C. Baker on June 12, 2024, pursuant to the Incentive Plan. The Stock Options have a strike price of $59.94 and vest on the earlier of June 12, 2025, the date of the next annual meeting of stockholder's of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 11, 2034.

F15 · derivative.exercise_date: Includes 12,517 Stock Options granted by the Issuer to Julian C. Baker on June 12, 2024, pursuant to the Incentive Plan. The Stock Options have a strike price of $59.94 and vest on the earlier of June 12, 2025, the date of the next annual meeting of stockholder's of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 11, 2034.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to Julian C. Baker of 2,830 RSUs on Table I and 12,517 Stock Options on Table II. These grants of 2,830 RSUs and 12,517 Stock Options for Julian C. Baker are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-073677 · ownership.xml · derivative · entry 8

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,517

Underlying: Common Stock · 12,517 shares

Expires 2034-06-11

F15 · derivative.exercise_price: Includes 12,517 Stock Options granted by the Issuer to Julian C. Baker on June 12, 2024, pursuant to the Incentive Plan. The Stock Options have a strike price of $59.94 and vest on the earlier of June 12, 2025, the date of the next annual meeting of stockholder's of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 11, 2034.

F15 · derivative.exercise_date: Includes 12,517 Stock Options granted by the Issuer to Julian C. Baker on June 12, 2024, pursuant to the Incentive Plan. The Stock Options have a strike price of $59.94 and vest on the earlier of June 12, 2025, the date of the next annual meeting of stockholder's of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 11, 2034.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the non-qualified options to purchase Common Stock of the Issuer ("Stock Options") reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to Julian C. Baker of 2,830 RSUs on Table I and 12,517 Stock Options on Table II. These grants of 2,830 RSUs and 12,517 Stock Options for Julian C. Baker are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000950170-24-073677 · ownership.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,182,605

F10 · shares: On May 12, 2024, the Funds, together with FBB, FBB2, FBB3, Felix J. Baker, and Julian C. Baker entered into a Stock Purchase Agreement with the Issuer (the "Stock Purchase Agreement") pursuant to which, subject to the completion of a modified "Dutch auction" tender offer (the "Tender Offer") and other terms and conditions stated in the Stock Purchase Agreement, the Funds agreed to sell to the Issuer and the Issuer agreed to purchase from the Funds shares of Common Stock of the Issuer in a quantity and for a price that were dependent on the outcome of the Tender Offer.

F11 · shares: On June 13, 2024, the Issuer announced the results of the Tender Offer. Based on these results and pursuant to the terms of the Stock Purchase Agreement, Life Sciences sold 5,283,206 shares of Common Stock to the Issuer, for proceeds of $316,992,360, and 667 sold 175,977 shares of Common Stock to the Issuer, for proceeds of $10,558,620, in each case subject to the terms of the Stock Purchase Agreement.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 11,510 shares of Common Stock previously issued to Julian C. Baker pursuant to the Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-073677 · ownership.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,811,926

F10 · shares: On May 12, 2024, the Funds, together with FBB, FBB2, FBB3, Felix J. Baker, and Julian C. Baker entered into a Stock Purchase Agreement with the Issuer (the "Stock Purchase Agreement") pursuant to which, subject to the completion of a modified "Dutch auction" tender offer (the "Tender Offer") and other terms and conditions stated in the Stock Purchase Agreement, the Funds agreed to sell to the Issuer and the Issuer agreed to purchase from the Funds shares of Common Stock of the Issuer in a quantity and for a price that were dependent on the outcome of the Tender Offer.

F11 · shares: On June 13, 2024, the Issuer announced the results of the Tender Offer. Based on these results and pursuant to the terms of the Stock Purchase Agreement, Life Sciences sold 5,283,206 shares of Common Stock to the Issuer, for proceeds of $316,992,360, and 667 sold 175,977 shares of Common Stock to the Issuer, for proceeds of $10,558,620, in each case subject to the terms of the Stock Purchase Agreement.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the non-qualified options to purchase Common Stock of the Issuer ("Stock Options") reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 11,510 shares of Common Stock previously issued to Julian C. Baker pursuant to the Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

SEC source: 0000950170-24-073677 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 33,465,811

F1 · shares: Includes 2,830 restricted stock units (each an "RSU") payable solely in common stock ("Common Stock") of Incyte Corporation (the "Issuer") granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") on June 12, 2024, pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan ("Incentive Plan"). The RSUs fully vest on the earlier of June 12, 2025, the date of the next annual meeting of stockholder's of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 11,510 shares of Common Stock previously issued to Julian C. Baker pursuant to the Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to Julian C. Baker of 2,830 RSUs on Table I and 12,517 Stock Options on Table II. These grants of 2,830 RSUs and 12,517 Stock Options for Julian C. Baker are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-073677 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,987,903

F1 · shares: Includes 2,830 restricted stock units (each an "RSU") payable solely in common stock ("Common Stock") of Incyte Corporation (the "Issuer") granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") on June 12, 2024, pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan ("Incentive Plan"). The RSUs fully vest on the earlier of June 12, 2025, the date of the next annual meeting of stockholder's of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the non-qualified options to purchase Common Stock of the Issuer ("Stock Options") reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 11,510 shares of Common Stock previously issued to Julian C. Baker pursuant to the Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to Julian C. Baker of 2,830 RSUs on Table I and 12,517 Stock Options on Table II. These grants of 2,830 RSUs and 12,517 Stock Options for Julian C. Baker are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000879169-24-000098 · wk-form4_1718381865.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,377

F1 · balance_after: This includes an aggregate of 55,340 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000097 · wk-form4_1718381833.xml · derivative · entry 2

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,517

Underlying: Common Stock · 12,517 shares

Expires 2034-06-11

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0000879169-24-000097 · wk-form4_1718381833.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,323

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000096 · wk-form4_1718381801.xml · derivative · entry 2

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,517

Underlying: Common Stock · 12,517 shares

Expires 2034-06-11

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0000879169-24-000096 · wk-form4_1718381801.xml · nonDerivative · entry 1

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,808

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000094 · wk-form4_1718381735.xml · derivative · entry 2

BRAWLEY OTIS W · CIK 0001213029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,517

Underlying: Common Stock · 12,517 shares

Expires 2034-06-11

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0000879169-24-000094 · wk-form4_1718381735.xml · nonDerivative · entry 1

BRAWLEY OTIS W · CIK 0001213029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,734

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000095 · wk-form4_1718381770.xml · derivative · entry 2

High Katherine A · CIK 0001631248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,517

Underlying: Common Stock · 12,517 shares

Expires 2034-06-11

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0000879169-24-000095 · wk-form4_1718381770.xml · nonDerivative · entry 1

High Katherine A · CIK 0001631248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,823

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.